#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glycogen storage disease type II Acute myeloid leukaemia recurrent Autoimmune disorder Acute respiratory distress syndrome Mucopolysaccharidosis I Glomerulonephritis membranoproliferative Malformation venous Non-Hodgkin's lymphoma refractory Synovial sarcoma metastatic Cutaneous T-cell lymphoma refractory Thymic carcinoma Keratosis follicular Uveal melanoma Wolfram syndrome Crohn's disease More trials…

    Learn about Rare Diseases

    Alport’s syndrome Sarcoma Combined immunodeficiency – Basic Information Vascular malformation – Life with Disease Paroxysmal nocturnal haemoglobinuria – Basic Information Immunodeficiency congenital – Trials in Disease Hereditary optic atrophy – Life with Disease Hepatoblastoma – Trials in Disease Netherton’s syndrome – Basic Information Angiosarcoma non-metastatic – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    TALADEGIB Mk-4830 Ranolazine Ceftazidime Exidavnemab L-Threonine Posdinemab Alnus Glutinosa Pollen Pitavastatin Calcium Viltolarsen Metformin Embonate Poa Pratensis Pollen Extract ATTR-01 Piritramide Abacavir Etrumadenant Progesterone, Micronised Colestyramine Cft1946 IMELASOMERAN More therapies…

    Learn about Your Condition

    Febrile neutropenia Apheresis Bladder cancer recurrent Altered state of consciousness Osteonecrosis of jaw Lung transplant Erythema multiforme Breast cancer stage IV Labour induction Glycogen storage disorder Arginase deficiency Strongyloidiasis Oedema peripheral HER2 positive gastric cancer Myasthenia gravis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

HER2 mutant non-small cell lung cancer

  • A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • HER2 mutant non-small cell lung cancer
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IIIA
    Investigated Drugs:
    • Pemetrexed Disodium
    • BNT327
    • Carboplatin
    Germany Italy Poland Spain

  • Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Pembrolizumab
    Belgium France Germany Greece Italy Poland +3

  • Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • HER2 mutant non-small cell lung cancer
    • Sarcoma
    • Head and neck cancer
    Investigated Drugs:
    • Zanidatamab
    France

  • Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 mutant non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Pembrolizumab
    Austria Belgium Denmark France Germany Italy +3

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!